GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer Ruchika Sharma21 Jan 2025 1:30 PM ISTLondon: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy...
JnJ gets USFDA nod for Rybrevant plus standard of care chemotherapy for lung cancer treatment Ruchika Sharma21 Sept 2024 4:00 PM ISTRaritan: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) in...
EMA Committee recommends Rybrevant in combo with chemotherapy for adult patients with lung cancer after failure of prior therapy Ruchika Sharma4 Aug 2024 11:00 AM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
US FDA expands Jemperli plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma2 Aug 2024 10:00 AM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and...
USFDA approves Merck Keytruda plus Carboplatin, Paclitaxel for Primary Advanced or Recurrent Endometrial Carcinoma Ruchika Sharma18 Jun 2024 11:30 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved...
AstraZeneca Imfinzi plus chemotherapy gets USFDA nod for mismatch repair deficient advanced or recurrent endometrial cancer Ruchika Sharma17 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has...
JnJ gets positive CHMP opinion for Rybrevant, chemotherapy combo for first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations Ruchika Sharma28 April 2024 12:30 PM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
GSK application for expanded indication of Jemperli plus chemotherapy accepted by USFDA for priority review Ruchika Sharma25 April 2024 12:40 PM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for...
Merck application for Keytruda plus chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma accepted by USFDA for priority review Ruchika Sharma22 Feb 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
Jemperli plus Zejula combo significantly improved progression-free survival in primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma20 Dec 2023 2:30 PM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
Janssen seeks USFDA nod for Rybrevant plus chemotherapy for patients with EGFR-Mutated Non-Small Cell Lung Cancer who progressed on or after Osimertinib Ruchika Sharma23 Nov 2023 2:30 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental Biologics License ...
Phase III trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma31 Oct 2023 11:35 AM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
